Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid.
The objective of this study was to ascertain whether "endothelium-derived relaxing factor" (EDRF) released from bovine intrapulmonary artery and vein is capable of directly activating soluble guanylate cyclase, thereby accounting for elevated vascular levels of cyclic GMP during EDRF release. Isolated arterial and venous rings, after equilibration and depolarization in bath chambers, were transferred to reaction tubes and incubated with soluble guanylate cyclase that had been purified to homogeneity from bovine lung. Addition of test agents to either bath chambers or enzyme reaction mixtures enabled the determination of their sites of action. Arterial and venous rings caused an endothelium-dependent 2- to 3-fold enzyme activation that was inhibited by methylene blue. Endothelium-dependent enzyme activation in artery but not vein was enhanced several-fold by acetylcholine in an atropine-sensitive manner. Bradykinin, which relaxes both artery and vein when endothelium is intact, activated guanylate cyclase upon addition of endothelium-intact rings to enzyme reaction mixtures. Vasoactive intestinal peptide, which causes endothelium-dependent relaxation of artery but not vein, also activated guanylate cyclase in the presence of endothelium-intact artery but not vein. Arachidonic acid activated the enzyme directly as well as through EDRF release from artery but not vein. Atrial peptides, prostacyclin, isoproterenol and nitroglycerin were inactive. Methylene blue was a powerful inhibitor of EDRF-elicited activation of guanylate cyclase but was without effect when rings were merely pretreated with methylene blue in bath chambers with no further addition to enzyme reaction mixtures. Thus, methylene blue did not interfere with the formation, release or chemical stability of EDRF, but rather inhibited its influence on guanylate cyclase. No agent was found to inhibit EDRF generation or release.(ABSTRACT TRUNCATED AT 250 WORDS)
Ignarro
L J
LJ
Harbison
R G
RG
Wood
K S
KS
Kadowitz
P J
PJ
D000109:Acetylcholine / Q000494:pharmacology*; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology*; D002417:Cattle; D004727:Endothelium / Q000502:physiology; D004789:Enzyme Activation; D006162:Guanylate Cyclase / Q000378:metabolism*; D006454:Hemoglobins / Q000494:pharmacology; D066298:In Vitro Techniques; D008751:Methylene Blue / Q000494:pharmacology; D009569:Nitric Oxide; D011335:Proadifen / Q000494:pharmacology; D011651:Pulmonary Artery / Q000502:physiology; D011667:Pulmonary Veins / Q000502:physiology; D011796:Quinacrine / Q000494:pharmacology; D012995:Solubility; D014665:Vasodilator Agents / Q000378:metabolism / Q000502:physiology*
D001095:Arachidonic Acids; D006454:Hemoglobins; D014665:Vasodilator Agents; D016718:Arachidonic Acid; D009569:Nitric Oxide; D001285:Atropine; D011335:Proadifen; D006162:Guanylate Cyclase; D011796:Quinacrine; D000109:Acetylcholine; D001920:Bradykinin; D008751:Methylene Blue